This post was originally published on this site
The company said it will prioritize development of its drug BXCL501, being evaluated for use in at-home settings for treatment of agitation related to schizophrenia, bipolar disorders and in patients with mild-to-moderate dementia due to probable Alzheimer’s disease.
Shares of the company were halted during premarket trading.